‪#‎SSc16‬ – Exclusive Interview with Colin Meyer, Reata Pharmaceuticals

Recent Posts

• FDA grants orphan drug status to BLR-200 for scleroderma
• 2 blood proteins may help detect lung issues in scleroderma patients
• Resilience may curb negative effects of feeling socially isolated: Study
• CABA-201 gets FDA orphan drug status as scleroderma treatment
• How scleroderma has changed my face, despite my best efforts
• T-helper cells may affect lung disease severity in SSc: Study 
• Joint inflammation, health-related quality of life linked in SSc: Study
• Cognitive difficulties, malnutrition can be common with scleroderma
• Frequency of muscle disease in SSc shows need for biomarkers: Study
• FDA fast track designation granted to Certa’s FT011 for scleroderma